Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
N4 Pharma PLC on Thursday said it bought a controlling interest in Nanogenics Ltd, a company with a lipid and peptide-based delivery system called Liptide.
N4 Pharma shares fell 32% to 0.95 pence each on Thursday morning in London.
N4 Pharma, a Derbyshire-based specialist pharmaceutical company focused on a delivery system for oncology, gene therapy and vaccines, said it funded the acquisition of a 71.25% interest for £250,000 via placing 35.0 million new shares at 1 pence per share.
The company said the stake will reduce to a 63.75% interest as management hit strategic milestones.
‘Nanogenic’s lead product candidate, ECP105 uses the Liptide platform to deliver a proprietary siRNA sequence to silence a fibrotic gene thereby enhancing the recovery of patients in post-glaucoma surgery,’ N4 Pharma explained. siRNA are short interfering RNA.
Copyright 2023 Alliance News Ltd. All Rights Reserved.